Shilpa Medicare Share Price
965.80+9.65 (+1.01%)
+128.74% past 1 Year
News
Shilpa Medicare starts voluntary recall of chemotherapy drug vials in US market
Equity
SHILPAMED
Shilpa Medicare guides for sustained growth, faster profitability and tax normalization
Equity
SHILPAMED
Shilpa Medicare plans FY27 human trials for first ADC biosimilar program
Equity
SHILPAMED
Shilpa Medicare targets Semaglutide DMF filing completion by first half FY27
Equity
SHILPAMED
Shilpa Medicare to begin European commercial supplies in 2H FY27
Equity
SHILPAMED
Shilpa Medicare management confident of stronger results by FY27
Equity
SHILPAMED
Shilpa Medicare onco block expansion progresses toward FY27 completion
Equity
SHILPAMED
Shilpa Medicare Q1 EBITDA rises with slight improvement in margin performance
Equity
SHILPAMED
Shilpa Medicare Q1 revenue surges year-on-year on strong operating performance
Equity
SHILPAMED
Shilpa Medicare reports higher quarterly net profit in Q1
Equity
SHILPAMED
Shilpa Medicare appoints Dr. Uday N. Harle as new Chief Executive Officer
Equity
SHILPAMED
Shilpa Medicare inks EU-GMP nivolumab biosimilar deal with Orion for Europe
Equity
SHILPAMED
Shilpa Medicare commissions advanced GMP oncology CDMO manufacturing facility
Equity
SHILPAMED
Shilpa Medicare forms strategic partnership with Gate2Brain for brain cancer therapy
Equity
SHILPAMED
Shilpa Medicare partners Gate2Brain for 30.4% stake to target brain cancer
Equity
SHILPAMED
Shilpa Medicare gets CDSCO approval for global Phase 3 plan for Albumin
Equity
SHILPAMED
Shilpa Medicare progresses ADC GMP facility qualification, commercial operations eyed FY27 Q1
Equity
SHILPAMED
Shilpa Medicare completes lab development of Teduglutide, validation by H1 FY27
Equity
SHILPAMED
Shilpa Medicare plans major oncology capacity expansion completing by end of FY27
Equity
SHILPAMED
Shilpa Medicare Q4 revenue rises 30 percent year-on-year to Rs 430 crores
Equity
SHILPAMED